(Q30368132)

21 June 2017

1 reference

title

Pandemic H5N1 influenza vaccine development: an update. (English)

1 reference

21 June 2017

0 references

1 reference

2

Wendy A Keitel

1 reference

21 June 2017

Hana M El Sahly

1

1 reference

21 June 2017

publication date

1 March 2008

1 reference

Expert Review of Vaccines

21 June 2017

published in

1 reference

21 June 2017

volume

7

1 reference

21 June 2017

issue

2

1 reference

21 June 2017

page(s)

241-247

1 reference

Emerging infections: pandemic influenza

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Observations on excess mortality associated with epidemic influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Morbidity and mortality characteristics of Asian strain influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Avian flu: multiple introductions of H5N1 in Nigeria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

H5N1 influenza: a protean pandemic threat

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Fatal infection with influenza A (H5N1) virus in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Non-pharmaceutical interventions for pandemic influenza, international measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Strategies for mitigating an influenza pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Comparison of influenza serological techniques by international collaborative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.2.241

21 January 2018

Identifiers

DOI

10.1586/14760584.7.2.241

1 reference

21 June 2017

1 reference